E2F1 and neoplasm: In a phase I clinical trial with 12 patients available for follow-up, treatment with ICOVIR-7, an adenovirus with a genetical deletion allowing the regulation of a gene by a tumor-specific promoter E2F-1, leads to two stable diseases, two minor responses, and one partial response, including one of the patients with breast cancer exhibiting a decrease or stabilization of tumor markers (74).